US Stock MarketDetailed Quotes
AVTX Avalo Therapeutics
- 14.9800
- +0.7800+5.49%
Close Apr 25 16:00 ET
- 16.0000
- +1.0200+6.81%
Post 19:48 ET
15.49MMarket Cap-131P/E (TTM)
16.3200High13.6500Low160.99KVolume13.9500Open14.2000Pre Close2.46MTurnover18.70%Turnover RatioLossP/E (Static)1.03MShares1130.400052wk High2.12P/B12.90MFloat Cap3.950152wk Low--Dividend TTM860.98KShs Float22031.7120Historical High--Div YieldTTM18.80%Amplitude3.9501Historical Low15.3060Avg Price1Lot Size
Avalo Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -14.69%-30.68M | 29.80%-2.77M | -219.39%-6.84M | 11.58%-11.03M | 37.44%-10.05M | 62.27%-26.75M | 76.96%-3.94M | 135.15%5.73M | 35.01%-12.47M | 12.28%-16.07M |
| Net income from continuing operations | 24.28%-31.54M | 16.75%-8.17M | -263.78%-5.23M | 36.91%-8.19M | 54.85%-9.96M | 50.63%-41.66M | 48.89%-9.81M | 118.35%3.19M | 24.07%-12.99M | 28.13%-22.05M |
| Operating gains losses | -87.65%720K | --600K | ---100K | --40K | --180K | --5.83M | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -4.82%158K | 22.86%43K | 20.59%41K | 36.67%41K | -50.75%33K | -89.98%166K | -88.14%35K | -92.53%34K | -93.42%30K | -85.14%67K |
| Deferred tax | -50.00%14K | -212.50%-9K | 60.00%8K | 16.67%7K | -11.11%8K | 27.27%28K | 144.44%8K | -44.44%5K | -40.00%6K | -57.14%9K |
| Other non cash items | 31.61%1.83M | --0 | 218.93%1.13M | 3.87%349K | 0.00%350K | 74.94%1.39M | 0.00%349K | 3.81%354K | --336K | --350K |
| Change In working capital | -15,300.00%-9.24M | 144.04%85K | -358.09%-3.64M | -173.34%-4.16M | -719.11%-1.52M | -102.11%-60K | 54.16%-193K | 196.71%1.41M | 73.40%-1.52M | -97.64%246K |
| -Change in receivables | -38.09%1.78M | 331.74%1.4M | -378.73%-1.49M | 52.82%813K | -56.06%1.06M | 795.65%2.88M | 31.79%-605K | -55.56%536K | 682.35%532K | 401.75%2.42M |
| -Change in inventory | 11.11%20K | --0 | 1,700.00%18K | -50.00%1K | -92.31%1K | 151.43%18K | 109.09%2K | -75.00%1K | 110.00%2K | 333.33%13K |
| -Change in prepaid assets | -58.69%447K | 156.40%97K | -74.58%195K | -38.27%492K | -8.71%-337K | 277.00%1.08M | 82.18%-172K | 124.27%767K | 11.47%797K | -258.97%-310K |
| -Change in payables and accrued expense | -178.81%-11.48M | -237.49%-1.3M | -648.15%-2.42M | -93.46%-5.5M | -18.90%-2.26M | -201.80%-4.12M | 111.38%947K | 67.40%-324K | 56.07%-2.84M | -117.17%-1.9M |
| -Change in other current liabilities | -744.44%-76K | -118.18%-24K | -83.33%-22K | -54.55%-17K | -152.00%-13K | 80.00%-9K | -320.00%-11K | 25.00%-12K | 38.89%-11K | 256.25%25K |
| -Change in other working capital | -20.45%70K | 75.14%-88K | --88K | --48K | --22K | --88K | ---354K | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -14.69%-30.68M | 29.80%-2.77M | -219.39%-6.84M | 11.58%-11.03M | 37.44%-10.05M | 62.27%-26.75M | 76.96%-3.94M | 135.15%5.73M | 35.01%-12.47M | 12.28%-16.07M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -40.00%-133K | 0 | 0 | 0 | -133K | 15.93%-95K | 0 | 51.85%-39K | -56K | 0 |
| Net PPE purchase and sale | 126.32%25K | --0 | --0 | 382.14%158K | ---133K | 15.93%-95K | --0 | 51.85%-39K | ---56K | --0 |
| Net other investing changes | ---158K | --0 | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -40.00%-133K | --0 | --0 | --0 | ---133K | 15.93%-95K | --0 | 51.85%-39K | ---56K | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 270.37%25.04M | -98.78%1K | 10.7M | 104.05%598K | 13.75M | -113.77%-14.7M | 7.89%82K | 0 | -169.66%-14.78M | 0 |
| Net issuance payments of debt | ---21.24M | --0 | ---15.24M | ---- | ---- | --0 | --14.81M | --0 | ---- | ---- |
| Net common stock issuance | 412.88%46.22M | 100.01%1K | --25.94M | --6.53M | --13.75M | -120.54%-14.77M | -17,914.63%-14.77M | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | -8.22%67K | --0 | --0 | ---- | ---- | -96.22%73K | -69.62%48K | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 270.37%25.04M | -98.78%1K | --10.7M | 104.05%598K | --13.75M | -113.77%-14.7M | 7.89%82K | --0 | -169.66%-14.78M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -75.72%13.32M | -39.97%10.31M | -43.84%6.45M | -56.49%16.88M | -75.72%13.32M | 187.15%54.86M | -76.11%17.18M | -71.72%11.49M | 0.52%38.8M | 187.15%54.86M |
| Current changes in cash | 86.11%-5.77M | 28.33%-2.77M | -32.14%3.86M | 61.81%-10.43M | 122.18%3.56M | -216.19%-41.55M | 77.35%-3.86M | -81.81%5.69M | -1,444.51%-27.31M | -182.45%-16.07M |
| End cash Position | -43.33%7.55M | -43.33%7.55M | -39.97%10.31M | -43.84%6.45M | -56.49%16.88M | -75.72%13.32M | -75.72%13.32M | -76.11%17.18M | -71.72%11.49M | 0.52%38.8M |
| Free cash flow | -14.28%-30.68M | 29.80%-2.77M | -220.20%-6.84M | 13.24%-10.87M | 36.45%-10.21M | 62.19%-26.85M | 76.97%-3.94M | 134.74%5.69M | 34.72%-12.53M | 12.38%-16.07M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg